Video Experimental Relacionado
Updated: Feb 26, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
8.2K
Objetivos biológicos emergentes en el asma tipo 2 y no tipo 2
Andrea E Davis1,2, Sarah Rhoads2, Michael E Wechsler2
1Division of Pulmonary, Allergy and Critical Care Medicine, the Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora.
Current opinion in pulmonary medicine
|February 24, 2026
Resumen
Las terapias novedosas tienen como objetivo lograr la remisión en el asma grave atacando nuevas vías y utilizando la administración de fármacos avanzada. Los biológicos actuales mejoran los síntomas pero a menudo no logran la remisión completa debido al asma
Área de la Ciencia:
- Neumología y Medicina Respiratoria
- Farmacología y Desarrollo de Fármacos
Sus antecedentes:
- El asma grave sigue siendo un importante desafío para la salud mundial, lo que contribuye significativamente a la morbilidad y la mortalidad.
- A pesar de los avances en el manejo del asma en las últimas dos décadas, lograr la remisión completa en casos graves sigue siendo esquivo para muchos pacientes.
Objetivo del estudio:
- Revisar los agentes y estrategias terapéuticas novedosos que se investigan para el manejo del asma grave.
- Explorar nuevos objetivos y mecanismos destinados a permitir que los pacientes con asma grave logren la remisión.
Principales métodos:
- Revisión de las estrategias actuales y emergentes de desarrollo de fármacos para el asma grave.
- Identificación de nuevos objetivos terapéuticos que incluyen la tirosina quinasa de Bruton, el ligando OX-40, la Janus quinasa, el receptor de quimiocinas CC 4 (CCR4) y el GATA-3.
- Análisis de nuevos enfoques como las formulaciones de acción ultralarga y las terapias biológicas combinadas.
Principales resultados:
- Los biológicos actuales para el asma han mejorado significativamente el control de los síntomas, la calidad de vida y han reducido el uso de esteroides sistémicos para muchos pacientes.
- Las estrategias novedosas de desarrollo de fármacos incluyen mecanismos de acción ultralarga, biológicos combinados, terapias orales y la focalización de nuevas vías.
- Los objetivos emergentes para el tratamiento del asma grave incluyen la tirosina quinasa de Bruton, el ligando OX-40, la Janus quinasa, el CCR4 y el GATA-3.
Conclusiones:
- Si bien los biológicos existentes ofrecen beneficios sustanciales, a menudo no logran inducir la remisión debido a limitaciones en el abordaje de la compleja fisiopatología del asma.
- Se está investigando activamente una amplia gama de mecanismos y objetivos terapéuticos novedosos para superar las limitaciones del tratamiento actual.
- La investigación futura se centra en enfoques innovadores para lograr la remisión sostenida y mejorar los resultados a largo plazo para los pacientes con asma grave.
Videos de Conceptos Relacionados
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
01:26Asthma-II: Pathophysiology and Classification
4.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K
01:20Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
51
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51